Axial Therapeutics™ is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurodegenerative diseases.
Year Founded: 2016
Key Executives:
• Stew Campbell, CEO
• Jeffrey Young, CFO
• Sarkis Mazmanian, Co-Founder
Year Invested: 2016
Investment Status: Current
Autistic children have long been known to have differences in their gut microbiota and as a...
Read moreAxial Therapeutics announced completion of enrollment in the TAPESTRY Autism Study, the Phase 2b clinical trial...
Read moreAxial Therapeutics announced it has received a research grant from The Michael J. Fox Foundation for...
Read moreAxial Therapeutics announced it is expanding the age eligibility criterion to include children ages 5 to...
Read moreAxial Therapeutics announced key promotions in its research and development organization. These promotions recognize the Axial...
Read moreA new trial sponsored by Axial Therapeutics will test whether a medication that targets gut bacteria...
Read moreAxial Therapeutics announced that A. Stewart Campbell, Ph.D., chief executive officer, will give a presentation titled,...
Read moreAxial Therapeutics announced that it is building on its clinical development science and operations capabilities through...
Read moreAxial Therapeutics Inc. announced that A. Stewart Campbell, Ph.D., Chief Executive Officer, will present in two...
Read moreAxial Therapeutics announced that A. Stewart Campbell, Ph.D., will participate in a panel entitled “The Next...
Read moreSeed Health and Axial Therapeutics announced a joint development program targeting the microbiome-gut-brain axis for mental health,...
Read moreAxial Therapeutics announced that A. Stewart Campbell, Ph.D., chief executive officer, will participate in a panel...
Read moreAxial Therapeutics announced that its scientific founder and California Institute of Technology (Caltech) Professor, Sarkis Mazmanian,...
Read moreAxial Therapeutics announced the publication of preclinical research demonstrating that microbial metabolites produced by gut bacteria...
Read moreAxial Therapeutics announced the publication in Nature Medicine of full results from its Phase 1b/2a clinical...
Read moreAxial Therapeutics announced that management will participate in a fireside chat at the 2020 RBC Capital...
Read moreAxial Biotherapeutics announced a $440,000 grant from the Michael J. Fox Foundation for Parkinson’s Research to...
Read moreKairos Ventures portfolio company Axial Biotherapeutics announced the appointment of Dr. Gregory T. Bates as Senior...
Read moreWe're excited to share that our portfolio company, Axial Biotherapeutics, has been selected as one of...
Read moreThis month, Axial Biotherapeutics announced the appointment of leading experts in the Autism Spectrum Disorders (ASD)...
Read moreAxial Biotherapeutics today announced the launch of the Company with a $19.15 million Series A round...
Read more